 | | Vol. 12.13 – 13 April, 2021 |
| |
|
|
| Brentuximab vedotin, an effective anti-CD30 antibody-drug conjugate approved for use in adults with classical Hodgkin lymphoma (HL), was introduced in this frontline trial to reduce prescribed radiation in children and adolescents with classical HL.
[Journal of Clinical Oncology] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| The authors identified that impaired minor intron excision via ZRSR2 loss enhanced hematopoietic stem cell self-renewal.
[Nature Genetics] |
|
|
|
| Scientists discovered that hallmarks of aging in HSCs and hematopoiesis begin to accumulate by middle age and that the bone marrow microenvironment at middle age induced and was indispensable for hematopoietic aging.
[Cell Stem Cell] |
|
|
|
| Researchers demonstrated that a key GAS6/AXL axis was highly activated in acute myeloid leukemia patient cells, particularly in stem/progenitor cells.
[Blood] |
|
|
|
| Scientists identified a novel role of PUMA in regulation of DNA repair in embryonic or iPSCs and immortalized hematopoietic progenitor cells after ionizing radiation.
[Signal Transduction and Targeted Therapy] |
|
|
|
| The authors report that a p300/CBP inhibitor, A-485, could overcome resistance to idelalisib in mantle cell lymphoma cells in vitro and in vivo.
[Acta Pharmacologica Sinica] |
| |
|
|
| Scientists tested the safety and efficacy of chimeric antigen receptor T cell therapy in refractory/relapsed acute myeloid leukemia.
[Clinical Cancer Research] |
|
|
|
| Investigators conducted a Phase I-II single arm, exploratory clinical trial from 2012 to 2016 in a single center. 15 patients aged from 1.9 to 16.4 years received an intrabone umbilical cord blood transplantation.
[Bone Marrow Transplantation] |
|
|
|
| Researchers evaluated procalcitonin and C-reactive proteinas markers of infection in hematopoietic stem cell transplantation patients.
[Leukemia Research] |
|  |
|
|
|
| Investigators present recent discoveries of the role of enhancer dynamics in mouse and human lymphoid development, and discuss how genetic and epigenetic alterations of enhancer function can promote leukemogenesis, and potential strategies for targeting the enhancer machinery in the treatment of acute lymphoblastic leukemia.
[Trends in Immunology] |
|
|
|
| The clinical importance of myelodysplastic syndromes (MDS) stem cells has been highlighted through the demonstration of selective persistence of MDS stem cells in patients at complete remission in response to therapy.
[Journal of Internal Medicine] |
|
|
|
|
| City of Hope and CytoImmune Therapeutics Inc. have entered into worldwide exclusive license agreements to several patent applications related to methods to generate large numbers of fully functional natural killer (NK) cells derived from umbilical cord blood and compositions of chimeric receptors (CAR) for targeting NK cells to tumors.
[CytoImmune Therapeutics, Inc. (BusinessWire, Inc)] |
|
|
|
| Arcellx, Inc. announced that the FDA has cleared the company’s Investigational New Drug (IND) application for ACLX-001, an engineered cell therapy for the treatment of multiple myeloma. ACLX-001 is the first clinical application of the company’s ARC-SparX platform of controllable and adaptable cell therapies.
[Arcellx, Inc.] |
|
|
|
|
|
|
|
| | Rutgers University – New Brunswick, New Jersey, United States |
|
|
|
| | American Association for Cancer Research – Boston, Massachusetts, United States |
|
|
|
| | Moores Cancer Center – La Jolla, California, United States |
|
|
|
| | University of Washington – Seattle, Washington, United States |
|
|
|
| | Moores Cancer Center – La Jolla, California, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
